Agilent Technologies licenses Caliper's LabChip® technology for diagnostic applications
Caliper Life Sciences Inc. and Agilent Technologies Inc. today announced an agreement granting Agilent a non-exclusive license to use a majority of Caliper's microfluidics patent estate for the development of clinical diagnostic applications on Agilent's 2100 Bioanalyzer, its 5100 Automated Lab-on-a-Chip platform and future instrument platforms. This new license agreement leverages the expertise and leading technology of Caliper and Agilent, enabling both companies to capitalize on the burgeoning diagnostics market. Under a separate new supply agreement, Agilent will use Caliper as its exclusive supplier of planar LabChip products for the 2100 Bioanalyzer and future instrument platforms for the next five years.
The diagnostics license agreement is part of Caliper's "LabChip DrivenTM" program, under which the company licenses its LabChip technology to developers of innovative products and services. Under the terms of this agreement, Agilent will pay an upfront licensing fee to Caliper, plus royalties on future sales of diagnostics LabChip products covered under the agreement. Further details of the two new agreements were not disclosed.
"Our years of success with the 2100 Bioanalyzer product line have demonstrated the long-term value of Caliper's LabChip technology for life science research, and this technology holds tremendous promise for other markets," said Chris Van Ingen, president, Life Sciences and Chemical Analysis, at Agilent. "Human clinical diagnostics is a major opportunity for Agilent, and we see synergy in combining microfluidics technology with Agilent's broad systems expertise. Our partnership with Caliper has been very productive, and we look forward to continuing to leverage both companies' expertise to deliver innovative solutions for our customers."
"Adding the Agilent diagnostic license to our LabChip Driven program is an important milestone for our business," said Kevin Hrusovsky, president and CEO at Caliper. "We believe our LabChip technology will play a leading role in the evolution of the diagnostics market as personalized medicine becomes mainstream. Where testing must be increasingly integrated, there is a real market need for cost-effective solutions that are able to migrate closer to the patient while still producing extremely high-quality results. Agilent is the ideal partner to help us leverage our technology into the diagnostics market."
"Our new long-term chip supply agreement with Agilent cements our position as a leading microfluidic chip supplier and signifies a continued collaborative and productive future relationship between our companies," added Hrusovsky.
Caliper also today updated revenue guidance for 2005. Based on preliminary financial data, Caliper expects second quarter revenue to be at the top end of the previously announced range of $17 million to $20 million. The company also reaffirmed its previous revenue projection for the full year of $84 million to $90 million.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
